research use only
Cat.No.S3140
| Related Targets | Adrenergic Receptor AChR 5-HT Receptor COX Calcium Channel Histamine Receptor Dopamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE) |
|---|---|
| Other Serotonin Transporter Inhibitors | Dapoxetine |
|
In vitro |
DMSO
: 57 mg/mL
(201.54 mM)
Water : 57 mg/mL Ethanol : 57 mg/mL |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 282.81 | Formula | C15H22N2O.HCl |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 101152-94-7 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CCN(CC)C(=O)C1(CC1CN)C2=CC=CC=C2.Cl | ||
| Targets/IC50/Ki |
norepinephrine transporter (NET)
77 nM
norepinephrine transporter (SERT)
420 nM
|
|---|---|
| In vitro |
Milnacipran is mainly excreted in the urine as the parent and glucoronide (> 80%), and only a small fraction (< 10%) is metabolized via N-de-ethylation by the CYP3A4 enzyme. Milnacipran at high concentration can inhibit certain ligand-gated ion-channel (LGIC) receptors, including NMDA, 5-HT3A and nACh receptors, with IC50 of 58.4 μM, 185 μM, 14.3 μM.
|
| In vivo |
Milnacipran (10 and 30 mg/kg, PO) causes a dose-related increase in the extracellular levels of 5-HT and NA in the medial prefrontal cortex of rats. Milnacipran (30 and 60 mg/kg, PO) significantly reduces the duration of both the immobility time in the forced swimming test and the freezing time in the conditioned fear stress test in rats, which are animal behavioral models for depression and anxiety, respectively. Milnacipran (<40 mg/kg i.p.) dose-dependently increases the extracellular levels of NA and 5-HT in hypothalamus of freely moving guinea pigs. Milnacipran administrated at 10 mg/kg and 40 mg/kg decreases NA metabolite MHPG levels by 57% and 47%, respectively, in hypothalamus of freely moving guinea pigs.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT01329406 | Unknown status | Osteoarthritis |
Analgesic Solutions|Forest Laboratories |
July 2011 | Phase 4 |
| NCT01328002 | Terminated | Primary Fibromyalgia |
Forest Laboratories|Cypress Bioscience Inc. |
April 30 2011 | Phase 2 |
| NCT01418651 | Terminated | Fibromyalgia |
Banner Health|Forest Laboratories |
March 2011 | Phase 3 |
| NCT01288807 | Completed | Fibromyalgia |
University of California San Diego|Forest Laboratories|US Department of Veterans Affairs |
February 2011 | Phase 4 |
| NCT00725101 | Completed | Fibromyalgia |
Eli Lilly and Company |
June 2008 | -- |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.